Recombinant proteins market is projected to grow at a CAGR of 11.14% by 2033: Visiongain Reports Ltd
May 05, 2023 11:43 ET
|
Visiongain Reports Ltd
Visiongain has published a new report: Recombinant Proteins Market: Forecasts by Products & Services (Cytokines & Growth Factors (Interferons (IFNs), Interleukins (ILS), Others), Antibodies,...
Compass Therapeutics Reports First Quarter Financial Results and Provides Corporate Update
May 04, 2023 08:30 ET
|
Compass Therapeutics
Initiated patient enrollment in a U.S. Phase 2/3 study of CTX-009 (DLL4 /VEGF-A bispecific antibody) in patients with advanced biliary tract cancers (BTC). Top line data is expected in the first half...
Compass Therapeutics to Participate in the H.C. Wainwright BioConnect Investor Conference at NASDAQ
April 26, 2023 08:30 ET
|
Compass Therapeutics
BOSTON, April 26, 2023 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics...
Recombinant proteins market is projected to grow at a CAGR of 11.14% by 2033: Visiongain Reports Ltd
April 20, 2023 11:52 ET
|
Visiongain Reports Ltd
Visiongain has published a new report: Recombinant Proteins Market:- Forecasts by Products & Services (Cytokines & Growth Factors (Interferons (IFNs), Interleukins (ILS), Others), Antibodies,...
Macomics Presents its ENIGMAC™ Discovery Platform for Gene to Function Target Validation of Novel Macrophage Therapies at AACR
April 17, 2023 13:30 ET
|
Macomics Limited
EDINBURGH, United Kingdom and CAMBRIDGE, United Kingdom, April 17, 2023 (GLOBE NEWSWIRE) -- Macomics Ltd, a leader in macrophage drug discovery has presented data demonstrating the power of its...
Antibody Testing Market to Grow US$17.7 Billion by 2033, Driven by Growing Demand for Accurate Diagnostics | Persistence Market Research
April 13, 2023 12:00 ET
|
Persistence Market Research
New York, April 13, 2023 (GLOBE NEWSWIRE) -- The global Antibody Testing Market is expected to generate US$ 7.9 billion in revenue by 2022, and is projected to grow at a CAGR of 7.6% to US$ 17.7...
Compass Therapeutics to Participate in the Cantor Fitzgerald Future of Oncology Symposium
March 28, 2023 08:30 ET
|
Compass Therapeutics
BOSTON, March 28, 2023 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics...
Monopar and NorthStar Announce Expanded Radiopharma Program, Positive Preclinical Results, and Visibility Toward Human Trials
February 27, 2023 07:00 ET
|
Monopar Therapeutics Inc.
WILMETTE, Ill. and BELOIT, Wis., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) (Wilmette, Ill.) and NorthStar Medical Radioisotopes, LLC (Beloit, Wis.), today announced...
Compass Therapeutics to Participate in the SVB Securities Global Biopharma Conference
February 02, 2023 08:30 ET
|
Compass Therapeutics
BOSTON, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics...
Compass Therapeutics Announces that the Phase 2 Data of CTX-009 in Combination with Paclitaxel in Patients with Biliary Tract Cancers (BTC) will be Presented at the ASCO GI Cancers Symposium on January 20, 2023
January 19, 2023 17:00 ET
|
Compass Therapeutics
Compass to Host Investor Event on Monday, January 23rd at 8:30am ET CTX-009 in combination with paclitaxel demonstrated a 37.5% overall response rate (ORR) in 24 patients with BTC treated in the...